This Medudy course is a video tutorial for physicians on the topic of “Lixisenatide in Early Parkinson’s Disease”, in which we summarize the latest and most important clinical studies for you.
Interestingly, diabetes treatments like glucagon-like peptide-1 (GLP-1) receptor agonists, which increase GLP-1 levels, have been associated with a lower prevalence of Parkinson’s disease.
Lixisenatide, a GLP-1 receptor agonist, demonstrated neuroprotective effects in animal models of Alzheimer’s and Parkinson’s disease.
Today’s study has therefore been specifically designed to analyse lixisenatide’s potential disease-modifying effects in early Parkinson’s patients who had already begun receiving standard therapy.
Note: All “speakers” appearing in the Medudy videos are AI-based avatars used for better didactics. The people on which the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by Medudy’s medical team.
At the end of this tutorial, you will know:
– the publication’s background on why this research question is relevant
– the publication’s study design and methods to answer this research question
– the publication’s results and main takeaways
– the publication’s conclusion as well as potential limitations
